Article: Mcl-1 expression in gestational trophoblastic disease correlates with clinical outcome: A differential expression study

File Download Links for fulltext
(May Require Subscription)
Supplementary

  • Basic View
  • Metadata View
  • XML View
TitleMcl-1 expression in gestational trophoblastic disease correlates with clinical outcome: A differential expression study
AuthorsFong, PY1
Xue, WC1
Ngan, HYS1
Chan, KYK1
Khoo, US1
Tsao, SW1
Chiu, PM1
Man, LS1
Cheung, ANY1
Keywordsc-DNA array
Gestational trophoblastic disease
Hydatidiform mole
Mcl-1
Issue Date2005
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741
CitationCancer, 2005, v. 103 n. 2, p. 268-276 [How to Cite?]
DOI: http://dx.doi.org/10.1002/cncr.20767
AbstractBACKGROUND. Hydatidiform moles (HMs) are abnormal pregnancies with a propensity for developing persistent disease in the form of gestational trophoblastic neoplasia (GTN), which requires chemotherapy. In previous studies, the authors demonstrated that low apoptotic activity was correlated with the progression of HM to GTN, and they hypothesized that some apoptosis-related genes may determine this progression. METHODS. The differential expression of apoptotic genes in HMs that subsequently developed into GTN was compared with the same expression in HMs that spontaneously regressed using a human apoptosis array; then, the expression was evaluated with real-time quantitative polymerase chain reaction analysis and immunohistochemistry using 54 clinical samples from patients with HMs who had follow-up data available. RESULTS. Using an apoptosis array, greater expression of Mcl-1, which is an antiapoptotic gene, was detected in HMs that subsequently developed into GTN. It was confirmed that the levels of Mcl-1 RNA expression (P = 0.017) and Mcl-1 protein expression (P < 0.001) in HMs that developed into persistent disease and required chemotherapy were significantly greater compared with the levels in HMs that regressed. Moreover, Mcl-1 immunoreactivity, which was detected predominantly in cytotrophoblasts, was correlated with the apoptotic index, as assessed with M30 cytoDeath immunohistochemistry, which is a good indicator of apoptotic events in the early-stage disease. CONCLUSIONS. The current results demonstrated that Mcl-1, as identified by a cyclic DNA array, may play a role in the pathogenesis of HMs and may have potential as a useful marker for predicting the clinical behavior of HMs. © 2004 American Cancer Society.
ISSN0008-543X
2011 Impact Factor: 4.771
2011 SCImago Journal Rankings: 0.578
DOIhttp://dx.doi.org/10.1002/cncr.20767
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorFong, PY
dc.contributor.authorXue, WC
dc.contributor.authorNgan, HYS
dc.contributor.authorChan, KYK
dc.contributor.authorKhoo, US
dc.contributor.authorTsao, SW
dc.contributor.authorChiu, PM
dc.contributor.authorMan, LS
dc.contributor.authorCheung, ANY
dc.date.accessioned2012-05-29T06:12:38Z
dc.date.available2012-05-29T06:12:38Z
dc.date.issued2005
dc.description.abstractBACKGROUND. Hydatidiform moles (HMs) are abnormal pregnancies with a propensity for developing persistent disease in the form of gestational trophoblastic neoplasia (GTN), which requires chemotherapy. In previous studies, the authors demonstrated that low apoptotic activity was correlated with the progression of HM to GTN, and they hypothesized that some apoptosis-related genes may determine this progression. METHODS. The differential expression of apoptotic genes in HMs that subsequently developed into GTN was compared with the same expression in HMs that spontaneously regressed using a human apoptosis array; then, the expression was evaluated with real-time quantitative polymerase chain reaction analysis and immunohistochemistry using 54 clinical samples from patients with HMs who had follow-up data available. RESULTS. Using an apoptosis array, greater expression of Mcl-1, which is an antiapoptotic gene, was detected in HMs that subsequently developed into GTN. It was confirmed that the levels of Mcl-1 RNA expression (P = 0.017) and Mcl-1 protein expression (P < 0.001) in HMs that developed into persistent disease and required chemotherapy were significantly greater compared with the levels in HMs that regressed. Moreover, Mcl-1 immunoreactivity, which was detected predominantly in cytotrophoblasts, was correlated with the apoptotic index, as assessed with M30 cytoDeath immunohistochemistry, which is a good indicator of apoptotic events in the early-stage disease. CONCLUSIONS. The current results demonstrated that Mcl-1, as identified by a cyclic DNA array, may play a role in the pathogenesis of HMs and may have potential as a useful marker for predicting the clinical behavior of HMs. © 2004 American Cancer Society.
dc.description.naturelink_to_OA_fulltext
dc.identifier.citationCancer, 2005, v. 103 n. 2, p. 268-276 [How to Cite?]
DOI: http://dx.doi.org/10.1002/cncr.20767
dc.identifier.doihttp://dx.doi.org/10.1002/cncr.20767
dc.identifier.epage276
dc.identifier.hkuros109806
dc.identifier.isiWOS:000226379000008
dc.identifier.issn0008-543X
2011 Impact Factor: 4.771
2011 SCImago Journal Rankings: 0.578
dc.identifier.issue2
dc.identifier.pmid15578716
dc.identifier.scopuseid_2-s2.0-12344276322
dc.identifier.spage268
dc.identifier.urihttp://hdl.handle.net/10722/148384
dc.identifier.volume103
dc.languageeng
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741
dc.publisher.placeUnited States
dc.relation.ispartofCancer
dc.relation.referencesReferences in Scopus
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshBase Sequence
dc.subject.meshBiopsy, Needle
dc.subject.meshCohort Studies
dc.subject.meshDna, Complementary - Analysis
dc.subject.meshDisease Progression
dc.subject.meshFemale
dc.subject.meshGene Expression Regulation, Neoplastic
dc.subject.meshGestational Trophoblastic Disease - Genetics - Pathology
dc.subject.meshHumans
dc.subject.meshHydatidiform Mole - Genetics - Pathology
dc.subject.meshImmunohistochemistry
dc.subject.meshIn Situ Nick-End Labeling
dc.subject.meshLogistic Models
dc.subject.meshMiddle Aged
dc.subject.meshMolecular Sequence Data
dc.subject.meshNeoplasm Proteins - Genetics - Metabolism
dc.subject.meshPregnancy
dc.subject.meshProbability
dc.subject.meshPrognosis
dc.subject.meshProto-Oncogene Proteins C-Bcl-2 - Genetics - Metabolism
dc.subject.meshRna, Neoplasm - Analysis
dc.subject.meshReverse Transcriptase Polymerase Chain Reaction
dc.subject.meshSensitivity And Specificity
dc.subject.meshTumor Markers, Biological - Analysis
dc.subject.meshUterine Neoplasms - Genetics - Pathology
dc.subjectc-DNA array
dc.subjectGestational trophoblastic disease
dc.subjectHydatidiform mole
dc.subjectMcl-1
dc.titleMcl-1 expression in gestational trophoblastic disease correlates with clinical outcome: A differential expression study
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong